Arcturus Therapeutics
ARCT
28 hedge funds and large institutions have $8.29M invested in Arcturus Therapeutics in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 24 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
26% less funds holding
Funds holding: 38 → 28 (-10)
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
44% less call options, than puts
Call options by funds: $296K | Put options by funds: $525K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
82% less capital invested
Capital invested by funds: $46.6M → $8.29M (-$38.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.32M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$810K |
| 3 |
Millennium Management
New York
|
+$580K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$527K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$470K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9.44M |
| 2 |
GL
GLG LLC
New York
|
-$3.71M |
| 3 |
SC
Sophrosyne Capital
New York
|
-$2.47M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$2.01M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$850K |
ARCT Hedge Fund Activity: Q4 2014 in Review
28 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2014, worth a combined $8.29M — down 82% from $46.6M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ARCT and 17 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.32M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $9.44M sold.
- 28 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2014, down from 38 in Q3 2014.
- Funds reported $8.29M of Arcturus Therapeutics stock for Q4 2014, down 82% quarter-over-quarter.
- 17 funds opened new Arcturus Therapeutics positions in Q4 2014 and 24 closed out, a net change of -7 holders.
- The largest Arcturus Therapeutics buyer in Q4 2014 was Baker Bros. Advisors, an estimated $1.32M added.
- The largest Arcturus Therapeutics seller in Q4 2014 was JP Morgan Chase, an estimated $9.44M sold.
Based on aggregated 13F filings for Q4 2014.